Rui Castro

Leila Akkari herself spoke about the tumour microenvironment in the context of liver cancer evolution, with Serena Vegna delcing deeper into genetic differences affecting the TME

Excited for #EASLCongress 2025! 🤩

As always, starting with the Basic Science Seminar, this year on Liver Tumours, Exposomics and Personalized Therapies, organised by Leila Akkari, @boulterlab.bsky.social and Jesus Bañales

@easlnews.bsky.social

BS @easlnews.bsky.social Congress

Wed 7🗓️Whole-day seminar plus a wet lab on spatial biology (NEW THIS YEAR‼️)
Thu 8🗓️State of the Art by Lars Zender
Fri 9🗓️MTE sessions on MASLD & MetALD
Sat 10🗓️Microbiome session co-chaired by our own @debbieshawcross.bsky.social

& more!🔗https://tinyurl.com/4ky9r3x9

In HCC, eIF3f|ACSL4 was shown to promote tumour malignancy by promoting fatty acid biosynthesis, with its targeting increasing anti-PD-1 efficacy

👉https://www.journal-of-hepatology.eu/article/S0168-8278(25)00206-5/fulltext

@jhepatology.bsky.social

2️⃣ translational studies on surpassing therapeutic resistance in liver cancer in press @jhepatology.bsky.social

In CCA, cisplatin-induced INF2 degradation was identified as a mechanism of enhanced cisplatin resistance

👉https://journal-of-hepatology.eu/article/S0168-8278(25)00219-3/fulltext

In a related topic, more about MASLD in an amazing Nature Reviews Disease Primers article just published:

🔗 nature.com/articles/s41...

@jvlazarus.bsky.social

📢EASL Studio today!👇

In the week celebrating #IWD2025, Saskia van Mil, Sara Della Torre & Münevver Demir will address mechanisms driving sex disparities in MASLD

Tune in! 📺

🔗https://easl.eu/easl-studio-episode/s8e6/

& just published in @jhepatology.bsky.social

🧬Mitochondrial CMPK2 is upregulated in human & experimental MASH
📈Ensues disease progression through the Nlrp3 inflammasome & pyroptosis
💉Nordihydroguaiaretic acid is a novel CMPK2 inhibitor supressing MASH

📰 doi.org/10.1016/j.jh...

Great talk by YI E. Torrejón on how gut EV-kupffer cell interaction contributes to MASLD #SLDsummit

HFD gut-EVs carry Selenocysteine Lyase (SCLY) to Kupffer cells, attenuating pro-inflammatory activity. It also activates ZEB2, inhibiting fibrogenesis

@easlnews.bsky.social

Stijn Meijnikman on the role of auto-brewery 🍺🦠 in SLD

The goal for the future is to use personalised medicine to eliminate high-ethanol-producing bacteria (gut microbiota transplantation, phages, antibiotics, pre|probiotics)

@easlnews.bsky.social #SLDsummit @debbieshawcross.bsky.social #Liversky

Martinez-Chantar addresses potential mitochondria-targeting therapies in MASLD, focusing on:

🎯 Methylation-controlled J protein (MCJ)
🎯 Glutaminase 1 (GLS1)
🎯 Mg2+ transporter CNNM4

using GalNAc-siRNA conjugates 💉

@easlnews.bsky.social #SLDsummit #Liversky

Another great study, this time by Jerôme Eeckhoute: what drives hepatocyte-cholangiocyte transdifferentiation?

🔎 One requirement appears to be relieving epigenetic repression of cholangiocyte genes in hepatocytes ❗️

Agree! 👌🏼 Very interesting also to see several recent studies clustering patients based on extrahepatic complications and how this may help prognosis

🤩🤩🤩 Loved your presentation @dinatiniakos.bsky.social ! Great overview of where liver biopsy and pathology fits within the new MASLD nomenclature; and what the future holds with upcoming innovations! 👏🏼

@rautoupe.bsky.social provides an update on endothelium-platelet interactions in SLD:

🎯 LSEC capillarisation increases with liver fibrosis in MASLD
🎯 Aspirin improves MASLD
🎯 Likely by inhibiting platelet accumulation and/or platelet EV release

@easlnews.bsky.social #SLDSummit

Happy to join Bluesky.

My main priority will be to contribute building a community of patient-oriented liver lovers.

I also want to post about humanism, creativity, photos….

I was playing this morning to create a logo for the liver community.

Cheers to all.

Young Investigator Poster Tour @easlnews.bsky.social #SLDSummit

Huge attendance and interest! 👏🏼

@tom-marjot.bsky.social @madsisraelsen.bsky.social

Alcohol use disorders increase after bariatric surgery. Why?

🎯 Increased consumption, sure, but also:
🎯 Alcohol pharmacokinetics
🎯 Gut hormone secretion changes

Anja Geerts @easlnews.bsky.social #SLDSummit #liversky

🎯Lancet Review Series 2024
@thelancet.bsky.social

Natural history and progression of metabolic dysfunction-associated steatotic liver disease

Image: MASLD progression

Read more
www.thelancet.com/journals/lan...

The first Young Investigator selected talk @ the #SLDSummit is pure basic science 😍

Erika Paolini used spatial transcriptomics to map the metabolic zonation of hepatocytes in MASLD, showing that PNPLA3 affects zonation by impairing periportal function

🧫🔬⚗️🧬🧪

@easlnews.bsky.social #liversky

There is still a lot of debate on the fatty liver disease / SLD nomenclature change, almost 2 years after endorsement by the leading Hepatology societies.

Philip Newsome reflects on the importance to keep discussing the reasoning behind this change

@easlnews.bsky.social #SLDSummit #liversky

@easlnews.bsky.social #SLDSummit kick-off! 🏃🏻‍♂️‍➡️⚽️

Introductory session & welcoming by the organisers

Helena Cortez-Pinto, Christophe Moreno, Bart Staels & Gema Martinez

FIRST BlueSky post

Thrilled to be back at AASLD/EASL masterclass

In just an hour our incredible team combined their different skills/interests into one beautiful team science proposal

GO TEAMMAIT study 🥇

#LiverSky

EASL|AASLD Masterclass in Savannah, Georgia!

Had so much fun talking about science communication and social media together with Patricia Bloom!

#LiverSky